Last reviewed · How we verify
QIV control
QIV control is a vaccine that stimulates the body's immune system to produce antibodies against the influenza virus.
QIV control is a vaccine that stimulates the body's immune system to produce antibodies against the influenza virus. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | QIV control |
|---|---|
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
QIV control is a quadrivalent influenza vaccine that contains antigens from four different influenza viruses. This vaccine works by introducing small, harmless pieces of the influenza virus to the body, which triggers an immune response and helps the body produce antibodies to fight the virus.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle or joint pain
- Fever
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QIV control CI brief — competitive landscape report
- QIV control updates RSS · CI watch RSS
- Institute of Medical Biology, Chinese Academy of Medical Sciences portfolio CI